Efficacy and Safety of Sulfonylurea Use in Permanent Neonatal Diabetes Due to KCNJ11 Gene Mutations: 34-Month Median Follow-Up

Familial Permanent Neonatal Diabetes with KCNJ11 Mutation and the Response to Glyburide Therapy - A Three-Year Follow-Up

(2011) J. Begum-Hasan et al.   JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM

Tooth Discoloration in Patients With Neonatal Diabetes After Transfer Onto Glibenclamide: A previously unreported side effect

(2009) J. Kumaraguru et al.   DIABETES CARE

Diabetic retinopathy in permanent neonatal diabetes due to Kir6.2 gene mutations: the results of a minimum 2-year follow-up after the transfer from insulin to sulphonylurea

(2009) T. Klupa et al.   DIABETIC MEDICINE

Role of Advanced Glycation End Products (AGEs) and Oxidative Stress in Diabetic Retinopathy

(2008) Sho-ichi Yamagishi et al.   CURRENT PHARMACEUTICAL DESIGN

Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation

(2008) A. S. Slingerland et al.   DIABETIC MEDICINE

The G53D Mutation in Kir6.2 (KCNJ11) Is Associated with Neonatal Diabetes and Motor Dysfunction in Adulthood that Is Improved with Sulfonylurea Therapy

(2007) Joseph C. Koster et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM